Prostate artery embolization has garnered much attention as a promising treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. We aim to provide an up-to-date review of this minimally invasive technique, including discussion of potential benefits and technical challenges. Current evidence suggests it is a safe and effective option for patients with medication-refractory urinary obstructive symptoms who are poor surgical candidates or refuse surgical therapy. Larger, randomized studies with long-term follow-up data are needed for this technique to be formally established in the treatment paradigm for benign prostatic hyperplasia.
Prostate artery embolization (PAE) is becoming an increasingly well-recognized therapeutic modality in the management of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Although the procedure has not yet been widely adopted, a growing body of evidence suggests it represents an innovative, effective, and safe alternative to transurethral resection of the prostate (TURP) and open prostatectomy as well as minimally invasive surgical therapies such as Holmium Laser Enucleation of the Prostate and photoselective vaporization of the prostate. Thus, it has garnered much interest in both the interventional radiologic and urologic communities. This article provides an up-to-date review of PAE in the treatment of LUTS secondary to BPH.
Background
LUTS typically include incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia. BPH represents the most common cause of LUTS, with more than 50% of men 60-69 years of age and as many as 90% 70-89 years of age experiencing such symptoms [1] . BPH symptoms are quantified by the International Prostate Symptom Score (IPSS), which assigns a severity score of 0-5 to each of the 7 LUTS symptoms. A total score of 0-7 is considered mild, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] is moderate, and 20-35 is severe [2] . An additional eighth question deals with patientperceived quality of life related to urinary symptoms, and is assigned a score of 0 (delighted) to 6 (terrible).
Existing Treatment Paradigm
The goal of treatment is to facilitate quality of life and to avoid the potential sequelae of bladder outflow obstruction, including acute urinary retention and recurrent urinary tract infection. Pharmacotherapy with alpha-blockers or 5-alphareductase inhibitors is usually the first line option for symptomatic patients. Patients who cannot tolerate pharmacotherapy, who develop complications of BPH, or whose disease is severe or refractory to treatment are considered for surgical intervention.
TURP remains the gold standard surgical therapy for BPH, with reported IPSS reduction of up to 70% [3, 4] . However, as many as 20% of patients can have significant complications including sexual dysfunction, perioperative bleeding requiring blood transfusion, and incontinence [3, 4] . Open prostatectomy has traditionally been reserved for prostates larger than 80-100 cm 3 , but carries with it significant morbidity and requires extended hospitalization. Several other less invasive techniques have been popularized in the past few years, including intraprostatic stents, transurethral needle ablation, transurethral microwave therapy, Holmium Laser Enucleation of the Prostate and photoselective vaporization of the prostate. However, none of these newer techniques have been shown to be superior to TURP from a cost-benefit standpoint, and none of them have supportive long-term efficacy data [5, 6] .
PAE

History and Expanding Research
Embolization of internal iliac artery branches has been successfully used to manage severe prostatic hemorrhage secondary to prostate cancer or BPH for over 30 years [7e10] . However, it was not until 2000 that the first case documenting therapeutic effect of PAE on BPH was published [9] . The premise behind PAE is simple: distal occlusion of the arteries supplying the prostate results in ischemic necrosis and reduction in gland volume [11] . The resultant effect is improvement in the objective and subjective parameters of voiding. PAE began to be studied for primary control of LUTS related to BPH after feasibility and safety from trials in dogs and pigs were established [12e14] .
The first intentional treatment of BPH with PAE in humans was performed by Carnevale et al [15] in 2008, wherein the procedure achieved the return of spontaneous urination in 2 catheter-dependent patients. Multiple nonrandomized trials have since been published, from various institutions and multiple countries, all of which have affirmed the efficacy and the safety of the procedure. An extensive search of English language online databases (Medline and PubMed) was performed for articles from January 2000 to October 2015. A comprehensive set of search terms including ''prostate,'' ''embolization,'' ''lower urinary tract symptoms,'' ''benign prostatic enlargement,'' and ''benign prostatic hyperplasia'' were used. In total, 11 studies (randomized and nonrandomized trials) on PAE for LUTS were identified with published findings [16e27]. See Table 1 for baseline characteristics of human PAE studies and Table 2 for a summary of outcomes of PAE studies published to date.
Summing all the studies included in this review, a total of 741 patients have undergone PAE and have been reported in the literature. Most of these studies have been single centre and nonrandomized. All 11 studies demonstrated consistent and significant IPSS reduction at 1 year post-PAE, with IPSS improvement ranging from 12-21 points. Quality of life improvement is also consistent, with bother score reduction ranging from 2.4-2.9 points, which generally equates to improvement from unhappy to mostly satisfied. Urinary flow rate improvement has been more heterogeneous, ranging from 32%-227%.
The largest study of PAE, with the longest follow-up, was published by Pisco et al [17] in 2013. It reported on 255 patients with a history of symptomatic BPH, refractory to pharmacologic treatment for at least 6 months, who underwent PAE as an alternative to surgery. Technical success [19] 65.2 (48-81) 93.9 (25.9-274) Polyzene F-coated hydrogel (Embozene) 100-400 96% Kurbatov [20] 66.4 129.3 Trisacryl gelatin microspheres (Embospheres) 300-500 100% Grosso [21] 75.9 (51-90) N/A Trisacryl gelatin microspheres (Embospheres) 300-500 75% Somani [22] 64 (54-74) 94.9 Nonspherical PVA N/A 90% Assis [23] 64.8 (53-77) 135.1 (90.3-252) Trisacryl gelatin microspheres (Embospheres) 300-500 94% Wang [24] 71.5 (56-85) 96.5 (50-168) Nonspherical PVA 100 95% Gao [25] 67.7 64.7 Nonspherical PVA 355-500 84% Carnevale [26] 62.0 (46-75) 64.6 (34-97) Trisacryl gelatin microspheres (Embospheres) 300-500 93% Li [27] 74. 3 , there has been great interest in the use of PAE for patients with large prostates. This was studied in 3 recent studies, in which the patients had severe obstructive symptoms at baseline, and average prostate volume was larger than 90 cm 3 . All 3 studies showed significant improvements of 12 to 15 points in IPSS and quality of life score improvements of 2 to 4 points, and no major complications were encountered. Two other recent studies, which compared outcomes of PAE in large size versus medium size prostates, reiterated that PAE is safe and effective in large prostates [19, 24] ; indeed, 1 of the studies demonstrated more improvement in patients with the larger prostates [24] , and PAE has been successfully used for prostates up to 274 cm 3 in size.
Randomized Controlled Trials
To date, only 2 randomized controlled trials have been published to compare PAE to TURP. In 2014, Gao et al [25] , assigning 57 patients each to PAE and TURP, found all voiding parameters to be similarly improved by both treatment modalities. Technical failures (5.3% vs 0%) and clinical failures (9.4% vs 3.9%) were more common with PAE, whereas substantial bleeding (3.8%) and transurethral resection syndrome (1.9%) occurred only with TURP. PAE recipients were less likely to require urethral catheterization and required a shorter hospital stay. More recently, Carnevale et al [26] published results of a small, single-centre, randomized trial comparing TURP to PAE with addition of a third arm, consisting of patients who underwent a modified PAE, the so-called PErFecTED (Proximal Embolization First, Then Embolize Distal) technique [28] . Among the 3 study treatment groups, mean post-treatment IPSS was significantly lower among TURP and PErFecTED patients than among conventional PAE patients but not significantly different between TURP and PErFecTED PAE patients. Although their results show that TURP results in significantly higher urinary flow postprocedure than original or PErFecTED PAE, this benefit came at the expense of inpatient hospitalization and a greater number and severity of adverse events [26] .
Additional randomized controlled trials are underway in the United States and elsewhere around the world. Pisco et al are lead investigators in a randomized trial assessing PAE, scheduled to release early results in 2016. An industrysponsored prospective multisite clinical trial comparing PAE and TURP, under the direction of Carnevale et al, is enrolling candidates to reach its target of 186 patients [29] . The primary endpoint will be IPSS improvement at 12 months postprocedure [29] . Preliminary results show significant improvement, with increase in peak urinary flow of 32% (baseline urinary flow rates not provided).
d Proximal Embolization First, Then Embolize Distal (PErFecTED) technique, a modified version of the PAE technique [26] .
Making the Case for PAE
PAE has several inherent advantages over traditional surgical therapies. First, it is minimally invasive, usually performed via a single femoral artery puncture under conscious sedation rather than general anesthesia. In contrast to more invasive procedures, PAE can be done in the outpatient setting, enabling the patient to go home the same day. Technical success is high, having been achieved in 75%-94% of patients [18, 30] . Prolonged Foley catheterization is not needed after PAE, and pharmacologic BPH treatments are usually discontinued in the weeks after the procedure. Unlike TURP, where the complication rate is higher with increased gland volume (>80 cm 3 ), there does not appear to be an upper limit of prostate size that can be effectively treated with PAE [31] . Evidence from short and intermediate-term data on PAE suggests that this evolving technology can be used for large prostates with no additional risk of adverse events [20, 23, 24] .
Current Limitations and Challenges
Although PAE promises to be a viable therapeutic alternative for BPH, current evidence remains limited, and PAE for the treatment of BPH should, at present, be considered only in patients who have failed medical therapy and either refuse surgery or are contraindicated for surgery. It is also important to recognize that LUTS has a multitude of causes apart from BPH, including neurologic disease, bladder dysfunction, urinary tract infection, stone disease, and urethral stricture, among others; these conditions should be excluded prior to treatment, as PAE would be unlikely to be helpful for these conditions [32] . Further research is needed to define clear indications and contraindications for PAE. We expect that the ongoing prospective, multicentre, randomized, controlled trials will address these issues and allow for objective comparison of postintervention outcomes.
PAE is a technically challenging procedure, requiring detailed knowledge of pelvic arterial anatomy and advanced microcatheter skills. Occasionally, PAE cannot be achieved on at least 1 side, usually as a result of atherosclerosis, small vessel calibre, or tortuous anatomy. In these patients, who receive only unilateral embolization, clinical success may only be achieved in 50% of cases [33] . Even if PAE is technically successful (bilateral), as many as 25% of patients may not show a significant reduction in IPSS [30] . Also, the optimal embolic agent and size are yet to be determined. Spherical embolics of various types have shown success, as have nonspheroidal PVA particles, and particle sizes from 50-500 mm have been safely used. There is a theoretical efficacy advantage for smaller sized particles, as lack of clinical response post-PAE may be due to incomplete penetration of larger size particles into the periurethral prostatic parenchyma [27, 34] . Smaller embolic particle size may lead to greater gland ischemia along with obliteration of prostatic arteriolar anastomoses, which may reduce revascularization, prostate regrowth, and symptom recurrence [17] .
The prostatic arterial supply is closely related to that of the bladder and rectum; thus, there is potential for complications with nontarget embolization. This risk may be magnified with smaller particles, which have potential to cause distal penetration and occlusion of the bladder or rectal supply. Nontarget embolization may occur even if not detected during the procedure, as manifested by minor side effects that have been reported following PAE. These include dysuria, hematuria, hematochezia, hematospermia, and diarrhoea and are almost always self-limited [14, 35] . The major complication rate is minimal across the 11 reviewed studies, with only 1 reported case of bladder ischemia requiring surgical resection and 1 case of transient ischemic proctitis [17, 36] . While there is theoretical risk of obstruction of the penile artery supply, no incidences of penile ischemia or erectile dysfunction have been reported.
As is the case with any complex embolization procedure, fluoroscopic radiation dose should be an important consideration when planning these procedures. As outlined in the Society of Interventional Radiology (SIR) position statement on PAE, radiation exposure during the procedure must be carefully monitored, with patients at risk for skin burns in cases with prolonged fluoroscopy times [35] .
Societal Guidelines and Recommendations
SIR position statement published in 2014 notes that PAE is safe and efficacious based on short-term follow-up with high patient satisfaction and low reintervention rates [35] . However, SIR does advocate for performance of high-quality clinical research to expand the numbers of patients studied, extend the duration of follow-up, and compare PAE against existing surgical therapies [35] . The National Institute for Health and Care Excellence in the United Kingdom recommends that PAE for BPH should only be performed in the context of research and that evaluation of the patient should be undertaken by a multidisciplinary team (including an interventional radiologist and urologist) [37] . To our knowledge, major urologic societies such as American Urological Association and the European Association of Urology have not yet issued official position statements or guidelines on the role of PAE for BPH [2, 31] .
Conclusion
PAE for BPH is a novel and promising therapy with positive short-and intermediate-term outcomes data. Longterm data on PAE are not yet available, and there is a paucity of randomized controlled trials data. Ongoing trials comparing PAE with TURP will shed more light on how PAE should be incorporated into the treatment paradigm for BPH refractory to medical therapy.
